Acumen Pharmaceuticals, Inc. (ABOS)
ABOS moved a median of -0.79% 30 minutes after news, and -0.97% by the close. How ABOS actually reacts to news — the realized, point-in-time move the market made, measured across 288 labeled events over the last three years with zero look-ahead.
ABOS’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | -0.53% | 37% | 287 |
| 30-min | -0.79% | 37% | 288 |
| 60-min | -1.59% | 32% | 288 |
| to close | -0.97% | 38% | 284 |
| Middle 50% of ABOS reactions | -3.31% to +0.78% |
|---|---|
| Median reaction (30-min) | -0.79% |
| Measured reactions | 288 |
Half of all Acumen Pharmaceuticals, Inc. news events land between -3.31% and +0.78% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How ABOS reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Coverage initiations | 10 | -1.43% | 10% | 0.00% |
| Rating reiterations | 25 | -0.67% | 36% | -1.34% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 4 further classes were observed with fewer than 10 measured events and are not published. See how ABOS ranks against every other measured name →
That’s how ABOS usually reacts — get an email when it moves on news →Email me when ABOS moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to ABOS's baseline. Nothing else.
Recent ABOS events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 8-K Acumen Pharmaceuticals, For: Sep 16 | SEC filing · Form 8-K | SEC EDGAR | +0.34% | -10.62% | |
| Acumen Pharmaceuticals to Hold Virtual Investor Day on September 16, 2026 | Press release | GlobeNewswire | +1.36% | -0.34% | |
| Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences | Press release | GlobeNewswire | +0.00% | -1.28% | |
| Acumen Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Highlights | Press release | GlobeNewswire | +0.45% | +4.15% | |
| Form 10-Q Acumen Pharmaceuticals, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.00% | +2.00% | |
| Form 8-K Acumen Pharmaceuticals, For: Aug 12 | SEC filing · Form 8-K | SEC EDGAR | +0.45% | +4.15% | |
| Form S-8 Acumen Pharmaceuticals, | SEC filing · Form S-8 | SEC EDGAR | +0.00% | +2.00% | |
| Acumen Pharmaceuticals to Report Second Quarter Financial Results on August 12, 2026 | Press release | GlobeNewswire | -0.45% | +1.79% | |
| Acumen Pharmaceuticals Highlights Enhanced Brain Delivery™ (EBD™) Program Data and Early Alzheimer’s Disease Insights at the Alzheimer’s Association International Conference (AAIC®) 2026 | Press release | GlobeNewswire | -4.72% | -12.60% | |
| Acumen Pharmaceuticals to Present Data on Enhanced Brain Delivery™ (EBD™) Technology and Early Alzheimer’s Disease Insights at the Alzheimer’s Association International Conference (AAIC®) 2026 | Press release | GlobeNewswire | -1.48% | -4.82% | |
| JCR Pharmaceuticals Announces That Acumen Pharmaceuticals Has Exercised its Exclusive Option to Develop Therapeutic Candidates for Alzheimer’s Disease, Enabled by J-Brain Cargo® Technology Platform | Press release | Business Wire | +0.34% | -5.26% | |
| Acumen Pharmaceuticals Announces Nomination of Two Enhanced Brain Delivery™ (EBD™) Development Candidates for the Treatment of Alzheimer’s Disease | Press release | GlobeNewswire | +0.64% | -2.55% | |
| Form 8-K Acumen Pharmaceuticals, For: Jun 12 | SEC filing · Form 8-K | SEC EDGAR | +0.64% | -2.55% | |
| Form 8-K Acumen Pharmaceuticals, For: Jun 03 | SEC filing · Form 8-K | SEC EDGAR | +2.38% | -0.87% | |
| Acumen Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Highlights | Press release | GlobeNewswire | -2.33% | -3.88% | |
| Form 10-Q Acumen Pharmaceuticals, For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +2.02% | +0.40% | |
| Form 8-K Acumen Pharmaceuticals, For: May 12 | SEC filing · Form 8-K | SEC EDGAR | -2.33% | -3.88% | |
| Acumen Pharmaceuticals to Participate in the Bank of America Securities 2026 Health Care Conference | Press release | GlobeNewswire | -0.80% | +2.40% | |
| Acumen Pharmaceuticals to Report First Quarter Financial Results on May 12, 2026 | Press release | GlobeNewswire | +0.39% | +1.18% | |
| Form ARS Acumen Pharmaceuticals, For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | -1.69% | -3.38% | |
| Form DEF 14A Acumen Pharmaceuticals, For: Dec 31 | SEC filing · Form DEF | SEC EDGAR | -1.69% | -3.38% | |
| Form DEFA14A Acumen Pharmaceuticals, | SEC filing · Form DEFA14A | SEC EDGAR | -1.69% | -3.38% | |
| Form EFFECT Acumen Pharmaceuticals, | SEC filing · Form EFFECT | SEC EDGAR | +0.15% | +8.43% | |
| Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2025 and Business Highlights | Press release | GlobeNewswire | -5.86% | -0.39% | |
| Form 10-K Acumen Pharmaceuticals, For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +0.00% | -8.87% | |
| Form 8-K Acumen Pharmaceuticals, For: Mar 26 | SEC filing · Form 8-K | SEC EDGAR | -5.86% | -0.39% | |
| Form S-3 Acumen Pharmaceuticals, | SEC filing · Form S-3 | SEC EDGAR | +0.00% | -8.87% | |
| Form S-8 Acumen Pharmaceuticals, | SEC filing · Form S-8 | SEC EDGAR | +0.00% | -8.87% | |
| Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2025 Financial Results on March 26, 2026 | Press release | GlobeNewswire | +0.00% | -7.29% | |
| Acumen Pharmaceuticals Presents Studies on Enhanced Brain Delivery™, Biomarker Research, and Novel Antibodies at Advances in Alzheimer's Treatment at International Conference on Alzheimer’s and Parkinson’s Diseases 2026 | Press release | GlobeNewswire | -0.59% | -8.85% | |
| Acumen Pharmaceuticals Announces $35.75 Million Private Placement to Advance Potential Best-in-Class Molecules from Amyloid Beta Oligomer-Selective Enhanced Brain Delivery Portfolio | Press release | GlobeNewswire | -3.00% | -4.57% | |
| Form 8-K Acumen Pharmaceuticals, For: Mar 13 | SEC filing · Form 8-K | SEC EDGAR | -3.00% | -4.57% | |
| Acumen Pharmaceuticals to Participate in the Stifel 2026 Virtual CNS Forum | Press release | GlobeNewswire | +0.59% | +0.00% | |
| Acumen Pharmaceuticals to Showcase Advances in Alzheimer's Treatment at International Conference on Alzheimer’s and Parkinson’s Diseases 2026 | Press release | GlobeNewswire | -0.94% | +3.44% | |
| Form 8-K Acumen Pharmaceuticals, For: Jan 12 | SEC filing · Form 8-K | SEC EDGAR | -5.43% | -6.52% | |
| Acumen Pharmaceuticals Highlights Enhanced Brain Delivery™ Technology for Oligomer-Selective Antibodies and Recruitment Strategies for Phase 2 ALTITUDE-AD Clinical Trial at 18th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference | Press release | GlobeNewswire | +0.00% | -7.41% | |
| Acumen Pharmaceuticals to Present on Recruitment Strategies for Phase 2 ALTITUDE-AD Trial and Enhanced Brain Delivery Technology at 18th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference | Press release | GlobeNewswire | -0.63% | +3.75% | |
| Acumen Pharmaceuticals Announces First Participant Dosed in Phase 2 Open-Label Extension Study of Sabirnetug in People with Early Alzheimer’s Disease | Press release | GlobeNewswire | -1.73% | -8.67% | |
| Acumen Pharmaceuticals Reports Third Quarter 2025 Financial Results and Business Highlights | Press release | GlobeNewswire | -3.03% | -1.51% | |
| Form 10-Q Acumen Pharmaceuticals, For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | -0.53% | — | |
| Form 8-K Acumen Pharmaceuticals, For: Nov 12 | SEC filing · Form 8-K | SEC EDGAR | -3.03% | -1.51% | |
| Acumen Pharmaceuticals Appoints George Golumbeski, Ph.D., as Chairman of its Board of Directors | Press release | GlobeNewswire | -0.53% | +0.00% | |
| Form 8-K Acumen Pharmaceuticals, For: Nov 06 | SEC filing · Form 8-K | SEC EDGAR | -0.53% | +0.00% | |
| Acumen Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 12, 2025 | Press release | GlobeNewswire | +0.00% | -5.00% | |
| Acumen Pharmaceuticals to Participate in the Stifel Healthcare Conference | Press release | GlobeNewswire | +1.28% | +4.10% | |
| Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences | Press release | GlobeNewswire | -0.71% | -0.71% | |
| Acumen Pharmaceuticals Reports Second Quarter 2025 Financial Results and Business Highlights | Press release | GlobeNewswire | -0.02% | — | |
| Form 10-Q Acumen Pharmaceuticals, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -1.54% | -2.31% | |
| Form 8-K Acumen Pharmaceuticals, For: Aug 12 | SEC filing · Form 8-K | SEC EDGAR | -0.74% | — | |
| Acumen Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 12, 2025 | Press release | GlobeNewswire | +2.46% | +2.94% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the ABOS section they belong to.
Where else ABOS is measured.
ABOS earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Acumen Pharmaceuticals, Inc.'s median reaction calculated?
Every labeled ABOS news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 288 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 37% of ABOS's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does ABOS's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.